JP2008521806A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521806A5 JP2008521806A5 JP2007543121A JP2007543121A JP2008521806A5 JP 2008521806 A5 JP2008521806 A5 JP 2008521806A5 JP 2007543121 A JP2007543121 A JP 2007543121A JP 2007543121 A JP2007543121 A JP 2007543121A JP 2008521806 A5 JP2008521806 A5 JP 2008521806A5
- Authority
- JP
- Japan
- Prior art keywords
- radical
- group
- radicals
- compound
- propoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2-amino-1-hydroxyeth-1-yl radical Chemical class 0.000 claims 76
- 150000001875 compounds Chemical class 0.000 claims 43
- 150000003254 radicals Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 2
- 230000004094 calcium homeostasis Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- LPFKKNRVAFTENR-UHFFFAOYSA-N 3-[3-chloro-4-[2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl LPFKKNRVAFTENR-UHFFFAOYSA-N 0.000 claims 1
- LWMPOMSZJGBJOT-UHFFFAOYSA-N 3-[3-chloro-4-[2-[[4-[2-hydroxy-3-[2-(2-methoxyphenoxy)ethylamino]propoxy]-9h-carbazol-1-yl]-methylamino]ethoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound COC1=CC=CC=C1OCCNCC(O)COC(C=1C2=CC=CC=C2NC=11)=CC=C1N(C)CCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl LWMPOMSZJGBJOT-UHFFFAOYSA-N 0.000 claims 1
- UVSBDRRJOCXMPP-QFIPXVFZSA-N 3-[3-chloro-4-[3-[2-[4-[(2s)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethoxy]propoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCCCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl UVSBDRRJOCXMPP-QFIPXVFZSA-N 0.000 claims 1
- FIKNZEFYNKNAKF-UHFFFAOYSA-N 3-[3-chloro-4-[3-[[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]methoxy]propoxy]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1COCCCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl FIKNZEFYNKNAKF-UHFFFAOYSA-N 0.000 claims 1
- FYDFMFOMILPYLA-UHFFFAOYSA-N 3-[4-[2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]ethoxy]-3-chlorophenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1CCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl FYDFMFOMILPYLA-UHFFFAOYSA-N 0.000 claims 1
- AHNNKJCYHBXTGM-UHFFFAOYSA-N 3-[4-[2-[[4-[3-(tert-butylamino)-2-hydroxypropoxy]-9h-carbazol-1-yl]-methylamino]ethoxy]-3-chlorophenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C=1C=C(OCC(O)CNC(C)(C)C)C(C2=CC=CC=C2N2)=C2C=1N(C)CCOC(C(=C1)Cl)=CC=C1C1=NNC(=O)CC1 AHNNKJCYHBXTGM-UHFFFAOYSA-N 0.000 claims 1
- LPHTUGOMETZXKX-QFIPXVFZSA-N 3-[4-[3-[2-[4-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]phenyl]ethoxy]propoxy]-3-chlorophenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OC[C@@H](O)CNC(C)(C)C)=CC=C1CCOCCCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl LPHTUGOMETZXKX-QFIPXVFZSA-N 0.000 claims 1
- WUMDEDHGYLBFTD-UHFFFAOYSA-N 3-[4-[3-[[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]methoxy]propoxy]-3-chlorophenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1COCCCOC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl WUMDEDHGYLBFTD-UHFFFAOYSA-N 0.000 claims 1
- XTAVHBUXIIFHEA-FQEVSTJZSA-N 4-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]-n-[2-[[2-[2-chloro-4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetyl]amino]ethyl]benzamide Chemical compound C1=CC(OC[C@@H](O)CNC(C)(C)C)=CC=C1C(=O)NCCNC(=O)COC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl XTAVHBUXIIFHEA-FQEVSTJZSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000005840 aryl radicals Chemical class 0.000 claims 1
- 210000001992 atrioventricular node Anatomy 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- KQMJLUHMRFZKEY-NRFANRHFSA-N n-[2-[4-[(2s)-3-(tert-butylamino)-2-hydroxypropoxy]phenyl]ethyl]-2-[4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetamide Chemical compound C1=CC(OC[C@@H](O)CNC(C)(C)C)=CC=C1CCNC(=O)COC1=CC=C(C=2CCC(=O)NN=2)C=C1 KQMJLUHMRFZKEY-NRFANRHFSA-N 0.000 claims 1
- HZXRRWYLGCNFEB-UHFFFAOYSA-N n-[2-[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]ethyl]-2-[2-chloro-4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetamide Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1CCNC(=O)COC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl HZXRRWYLGCNFEB-UHFFFAOYSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- FLJSKMRBQZTAQT-UHFFFAOYSA-N n-[[4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl]methyl]-2-[2-chloro-4-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenoxy]acetamide Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1CNC(=O)COC1=CC=C(C=2CCC(=O)NN=2)C=C1Cl FLJSKMRBQZTAQT-UHFFFAOYSA-N 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63159804P | 2004-11-30 | 2004-11-30 | |
| PCT/US2005/040586 WO2006060127A2 (en) | 2004-11-30 | 2005-11-08 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008521806A JP2008521806A (ja) | 2008-06-26 |
| JP2008521806A5 true JP2008521806A5 (https=) | 2008-11-06 |
Family
ID=36218314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543121A Pending JP2008521806A (ja) | 2004-11-30 | 2005-11-08 | 心不全を治療するための混合型のＰＤＥ−阻害活性およびβ−アドレナリン作用性アンタゴニスト活性または部分アゴニスト活性を有する化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080090827A1 (https=) |
| EP (1) | EP1830852A2 (https=) |
| JP (1) | JP2008521806A (https=) |
| CA (1) | CA2588949A1 (https=) |
| WO (1) | WO2006060127A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| UA95644C2 (ru) | 2006-07-25 | 2011-08-25 | Сефалон, Инк. | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP2142498A2 (en) * | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| CN102223882B (zh) * | 2008-11-25 | 2016-02-03 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| EA036423B1 (ru) * | 2016-03-04 | 2020-11-10 | Оцука Фармасьютикал Ко., Лтд. | Производное 5-метил-6-фенил-4,5-дигидро-2h-пиридазин-3-она |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
| CA3018802A1 (en) | 2016-04-15 | 2017-10-19 | Abbvie Inc. | Bromodomain inhibitors |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1488330A (en) * | 1973-12-19 | 1977-10-12 | Smith Kline French Lab | Dihydropyridazinones |
| US4111935A (en) * | 1975-01-02 | 1978-09-05 | Smith Kline & French Laboratories Limited | 3-chloro-6-phenylpyridazine compounds |
| DE2609645A1 (de) * | 1976-03-09 | 1977-09-15 | Boehringer Sohn Ingelheim | Aminoalkylheterocyclen |
| DE3023369A1 (de) * | 1980-06-23 | 1982-01-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB8323553D0 (en) * | 1983-09-02 | 1983-10-05 | Smith Kline French Lab | Pharmaceutical compositions |
| JPS6193169A (ja) * | 1984-10-12 | 1986-05-12 | Sankyo Co Ltd | ピリダジノン誘導体及びその製法 |
| DE3934436A1 (de) * | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5641783A (en) * | 1993-11-12 | 1997-06-24 | Cell Therapeutics, Inc. | Substituted amino alcohol compounds |
| US5827893A (en) * | 1996-03-29 | 1998-10-27 | Lurie; Keith G. | Mechanical and pharmacological therapies to treat cardiac arrest |
| WO2004050657A2 (en) * | 2002-11-27 | 2004-06-17 | Artesian Therapeutics, Inc. | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE |
| US20070117978A1 (en) * | 2002-12-23 | 2007-05-24 | Artesian Therapecutics, Inc | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase |
| US20100168120A1 (en) * | 2006-04-28 | 2010-07-01 | Neuromedix Inc. | Salts of pyridazine compounds |
-
2005
- 2005-11-08 JP JP2007543121A patent/JP2008521806A/ja active Pending
- 2005-11-08 US US11/791,893 patent/US20080090827A1/en not_active Abandoned
- 2005-11-08 WO PCT/US2005/040586 patent/WO2006060127A2/en not_active Ceased
- 2005-11-08 EP EP05851464A patent/EP1830852A2/en not_active Withdrawn
- 2005-11-08 CA CA002588949A patent/CA2588949A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521806A5 (https=) | ||
| RU2440330C2 (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| CN100575330C (zh) | 新化合物 | |
| JP2008521805A5 (https=) | ||
| Lange et al. | Synthesis, biological properties, and molecular modeling investigations of novel 3, 4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists | |
| JP2012500189A (ja) | ビアリールアミノテトラリン | |
| JP5270542B2 (ja) | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 | |
| JP4869225B2 (ja) | 呼吸器疾患処置用の置換酸 | |
| CN1183114C (zh) | 喹啉衍生物及喹唑啉衍生物 | |
| CN1024662C (zh) | N-(取代的苄氧基)亚胺衍生物、它们的制备方法、它们的应用以及应用的方法 | |
| KR20050035873A (ko) | 아민 화합물 및 그 용도 | |
| CN1324353A (zh) | 新的脒衍生物,其制备方法,其作为药物的用途以及含有该化合物的药物组合物 | |
| CN1127504A (zh) | 具有除草活性的取代2-苯基吡啶 | |
| JP2008507532A5 (https=) | ||
| RU2008136553A (ru) | Производные бензотиазола в качестве агонистов бета2 адренорецептора | |
| CN1527812A (zh) | 具有除草活性的新的取代的苯胺衍生物 | |
| RU2005117789A (ru) | Производные 4,5-диарилтиазола в качестве лигандов св-1 | |
| WO2010011917A1 (en) | SEH AND 11β-HSD1 DUAL INHIBITORS | |
| CN1657524A (zh) | 取代唑类化合物及其制备与应用 | |
| JPWO2021118629A5 (https=) | ||
| US7365069B2 (en) | Pyrimidone derivatives | |
| US6156801A (en) | 2-phenoxyaniline derivatives | |
| WO1994025448A1 (fr) | Nouveau derive de bisoxadiazolidine | |
| CN101506159A (zh) | 具有crth2拮抗剂活性的化合物 | |
| HUT77534A (hu) | Pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |